AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts
AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts
Read moreTue, 06th Jul 2021 13:00
AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts
Read moreIN BRIEF: ValiRx inks evaluation agreement for breast cancer treatment
Read moreEARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips
Read moreTRADING UPDATES: Brave Bison, Strix Group see strong performances
Read more(Sharecast News) - Clinical-stage drug development company ValiRx announced on Thursday that it has ended its agreement over the evaluation of the 'KTH222' peptide as a drug candidate for treating patients with ovarian cancer.
Read moreUK shareholder meetings calendar - next 7 days
Read moreEXECUTIVE CHANGES: Ex-Coca-Cola exec, Cafe Rouge founder for Deliveroo
Read moreTRADING UPDATES: Focusrite sales soar; Gaming Realms in Slingo boost
Read more(Sharecast News) - Oncology consulting company Physiomics has entered into a new agreement with clinical-stage drug development company ValiRx, it announced on Monday, superseding the agreement between the two companies, which was announced in September 2011.
Read moreIN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics
Read moreIN BRIEF: ValiRx's VAL201 Patented For Treatment Of Metastatic Cancer
Read moreUK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter
Read moreUK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges
Read moreValiRx Loss Narrows In First Half Amid Reduction In Expenses
Read more